Alexion enters gene therapy agreement with Pfizer
28 July 2023 Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies Agreement furthers Alexion's ambition to transform patient outcomes with genomic medicine and provides synergistic opportunities across AstraZeneca Portfolio includes preclinical gene therapy programmes and enabling technologies with potential across several therapeutic areas Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy